Get the Stockscreener App
7.36
3.08%
0.22
Pre-market:
7.30
-0.06
-0.82%
Solid Biosciences Inc stock is traded at $7.36, with a volume of 2.06M.
It is up +3.08% in the last 24 hours and up +6.36% over the past month.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
See More
Previous Close:
$7.14
Open:
$7.27
24h Volume:
2.06M
Relative Volume:
1.78
Market Cap:
$724.59M
Revenue:
$14.79M
Net Income/Loss:
$-191.78M
P/E Ratio:
-3.7811
EPS:
-1.9465
Net Cash Flow:
$-172.86M
1W Performance:
+14.82%
1M Performance:
+6.36%
6M Performance:
+28.90%
1Y Performance:
+63.19%
1-Day Range:
$7.11
$7.48
1-Week Range:
$6.34
$7.48
52-Week Range:
$3.79
$8.8661
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
7.36 | 724.59M | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Guggenheim | Buy |
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan
Director at Solid Biosciences (SLDB) granted 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant - Stock Titan
Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences director granted 77,500 options | SLDB Insider Trading - Stock Titan
Solid Biosciences Shareholders Approve Directors and Share Increase - TipRanks
Solid Biosciences (NASDAQ: SLDB) shareholders approve doubling authorized stock - Stock Titan
Should I Buy SLDB (Solid Biosciences Inc.) | AI Analysis, Technical & News Insights - Kavout
SLDB: Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications - TradingView
Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan
Solid Biosciences Rises as Investors Focus on Rare-Disease Pipeline - Bez Kabli
H.C. Wainwright raises Solid Biosciences price target on FA trial progress - Investing.com UK
SLDB Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus
SLDB: Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead - TradingView
H.C. Wainwright raises Solid Biosciences price target on FA trial progress By Investing.com - Investing.com South Africa
Solid Biosciences And Nanomosaic Announce Co-Marketing Agreement To Advance Gene Therapy Delivery And Analytics - TradingView
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics - PR Newswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat - Traders Union
Watch Solid Biosciences CEO at two June healthcare investor events - Stock Titan
Solid Biosciences to Participate at Upcoming Investor Conferences - The Manila Times
Solid Biosciences (SLDB) Edges Higher, Testing Key Resistance After Recent GainsIchimoku Cloud - The Legal Advocate
Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference - Traders Union
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Surges 3.93% as Bullish Momentum BuildsCall Resistance - The Legal Advocate
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Solid Biosciences Inc. (SLDB) Q1 2026 Earnings: Wider Loss Reported as Pipeline Investment ContinuesUpward Estimate Revision - thelegaladvocate.com
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Q1 2026 Earnings: Wider-than-Expected Loss as Solid Biosciences Advances Gene Therapy PipelineEstimate Revision Count - newsline.com
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
SLDB Reiterated by Wedbush -- Price Target Maintained at $16.00 - GuruFocus
Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush - Moomoo
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Citigroup Maintains Solid Biosciences (SLDB) Buy Recommendation - MSN
Should You Sell Solid Biosciences (SLDB) After -10.09% Drop? 2026-05-15Double Bottom - newsline.com
Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18 - AD HOC NEWS
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne - Traders Union
Number of shareholders of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating - Moomoo
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):